Press Releases and Events
Velabs baut eigene Pipeline mit Lizenzdeal aus: Die Heidelberger Velabs Therapeutics GmbH will über das Dienstleistungsgeschäft hinaus auch eigene Medikamentenkandidaten entwickeln. Dafür lizenzierte der Antikörper-Screening-
- Velabs and alytas enter into a licence agreement for senescence (07.01.2020)
- Velabs and alytas enter into a cooperation for a novel immune-based therapy for obesity (03.09.2019)
- Velabs and Chiome enter into a Cooperation in GPCR-Specific Functional Antibody Screening (27.08.19)
- Velabs Secures EUR 3,0 mio in Series B Financing (27.06.19)
- Velabs and Chiome Bioscience cooperate in GPCR Specific Functional Antibody Screening (24.04.19)
- Velabs and BioMed X cooperate in Immunology (07.01.19)
- Accelerating Antibody Discovery (07.03.18)